1. Marketed pharmaceuticals reported to be tumorigenic in rodents;Davies;J. Am. Coll. Toxicol.,1995
2. ICH Harmonised Triparite Guideline, 1997. Testing for carcinogenicity of pharmaceuticals for human use. In: D'Arcy, P.F., Harron, D.W.G. (Eds.), Proceedings of The Fourth International Conference on Harmonisation Brussels 1997, Queen's University of Belfast, N. Ireland, pp. 949, 23-1–23-7.
3. Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses on the induced tumors;Mitsumori;Mol. Carcinogen.,1998
4. Mitsumori, K., Koizumi, H., Nomura, T., Yamamoto, S., 1998b. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for 6-month carcinogenicity studies. Pathol. Toxicol. (in press).
5. Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes;Saitoh;Oncogene,1990